Product Name

Oritavancin Diphosphate

Name: Oritavancin Diphosphate - LGM Pharma
SKU: 192564-14-0

CAS Number

192564-14-0

LGM Pharma is an API distributor. LGM Pharma can supply CGMP and/or DMF products, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, pharmacies, or any pharmaceutical companies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:

Oritavancin Diphosphate

CAS Number:

192564-14-0

Indication:

Investigated for use/treatment in bacterial infection and skin infections/disorders.

Mode of Action:

Oritavancin is a glycopeptide antibiotic. This class of drugs inhibit the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis. They bind to the amino acids within the cell wall preventing the addition of new units to the peptidoglycan. In particular they bind to acyl-D-alanyl-D-alanine in peptidoglycan.

Pharmacodynamics:

Oritavancin is an investigational glycopeptide antibiotic with bactericidal activity effective in treating infections caused by Gram-positive organisms. It treats complicated skin and skin structure infections. This new drug will be tested for treatment of bacteraemia and nosocomial pneumonia. It demonstrates similar activity to vancomycin, but it has stronger activity against Staphylococcus and Enterococcus. The pharmacokinetics and pharmacodynamics of oritavancin appear to be favourable and once-daily dosing is likely. The incidence of multi-drug resistant bacteria is increasing and explorations into additional treatment options are essential.

IUPAC:

(4''R)-22-O-(3-Amino-2, 3, 6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3'')-((4'-chloro(1, 1'-biphenyl)-4-yl)methyl)vancomycin phosphate(1:2) (salt)

ATC:

J01XA05

PubChem:

16129632

DrugBank:

DB04911

Formula:

C86-H97-Cl3-N10-O26.2H3-O4-P

Molecular Mass:

1989.1027

Synonyms:

(4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)'-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin phosphate (1:2) (salt), (4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)'-(p-(p-chlorophenyl)benzyl)vancomycin phosphate (1:2) (salt), LY 333328 diphosphate, LY333328 diphosphate, Orbactiv, Oritavancin diphosphate, UNII-VL1P93MKZN

General Reference:

Citron DM, Kwok YY, Appleman MD: In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci. Anaerobe. 2005 Feb-Apr;11(1-2):93-5. Epub 2004 Dec 10. Pubmed
Ward KE, Mersfelder TL, LaPlante KL: Oritavancin—an investigational glycopeptide antibiotic. Expert Opin Investig Drugs. 2006 Apr;15(4):417-29. Pubmed
Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006 Mar;50(3):994-1000. Pubmed
Mercier RC, Hrebickova L: Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev Anti Infect Ther. 2005 Jun;3(3):325-32. Pubmed
Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP: Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005 Jan;49(1):148-52. Pubmed
Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004 Oct;50(2):95-102. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210.

Ask us about this product

API’s From Quality Manufacturers:

Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
Premium quality GMP certified and fully accredited API manufacturing plants
Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
Regulatory and technical assistance towards any submission type based on specific customer requirements

Oritavancin Diphosphate

192564-14-0

Ask us about this product

API’s From Quality Manufacturers:

Find an API Product